Sarcoidosis Market to Grow at a Massive Growth Rate During the Forecast Period (2019-32) - Estimates DelveInsight | Key Companies - Xentria (XTMAB-16), aTyr Pharma (Efzofitimod), Novartis (CMK389), Kinevant Sciences (Namilumab), and Others

As per DelveInsight, the Sarcoidosis Market size in the 7MM was USD 499.5 million in 2020, which is anticipated to increase by 2032. Some of the key factors, such as the growing number of sarcoidosis cases and the launch of emerging therapies, are expected to contribute directly to the market growth in the coming years. Some of the key pipeline products in clinical development stages include ATYR1923, Uptravi, Tyvaso, and others. The emergence of new products in the pipeline will further stimulate market growth in the future.

DelveInsight's "Sarcoidosis Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Sarcoidosis Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Sarcoidosis market report covers emerging drugs, treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Sarcoidosis: An Overview
Sarcoidosis is a multisystem granulomatous inflammatory disease, with lungs and intrathoracic lymph nodes being the most frequently affected sites. Patients typically experience fatigue, weakness, and dyspnea. Furthermore, respiratory muscle weakness, secondary to granulomatous inflammation, is associated with dyspnea and decreased quality of life (QoL). The presentation of sarcoidosis varies considerably from mild, acute self-limiting disease to chronic disease involving several organs and causing severe symptoms and functional impairment.

Patients with advanced sarcoidosis may develop pulmonary hypertension for a variety of reasons. Sarcoidosis-associated pulmonary hypertension (SAPH) is a major complication of sarcoidosis and is associated with significant morbidity and mortality. Over the past few years, increased recognition has led to more frequent identification of SAPH patients.

Sarcoidosis Market Key Facts
Considering the increasing prevalence of phenotypically heterogeneous disease sarcoidosis, the significant burden the disease exhibits on the quality of life (QoL) of patients together with the increasing sarcoidosis-related mortality over time, it is imperative to bring treatment options that can help improve the QoL of sarcoidosis patients and improve the disease outcomes.
Among the 7MM, the US accounted for 72% of the overall market size of Sarcoidosis in 2020.
Among the EU5, Germany had the largest market share in 2020, followed by Italy and France, whereas Spain had the smallest share.
The total prevalent cases of sarcoidosis in 2020 were 249,000+ in the 7MM, out of which the highest cases were observed in the United States.
In 2020, there were 154,727 prevalent cases of sarcoidosis in the United States.
In the United States, sarcoidosis cases were higher in females than males. In 2020 there were 64,985 males and 89,742 females affected with sarcoidosis.
The EU5 countries accounted for 85,600+ cases, whereas Japan had 8,900+ cases in 2020.
Among EU5 countries, Germany had the highest number of prevalent cases of sarcoidosis (29,708 cases) in 2020.
In Japan, the prevalence and incidence of sarcoidosis are low and more severe than in western countries. According to an article by Terasaki et al. (2019), in Japan, the prevalence of sarcoidosis was estimated to range from 7.5 to 9.3 patients in 100,000 people, and the annual incidence was about 1 in 100,000 people.

Sarcoidosis Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Sarcoidosis market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Sarcoidosis market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How Sarcoidosis Market will Grow by 2032:
https://www.delveinsight.com/report-store/sarcoidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Sarcoidosis Epidemiology
The epidemiology section covers detailed insights into the historical and current Sarcoidosis patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Sarcoidosis Epidemiology Segmented by -
Prevalent Cases of Sarcoidosis in the 7MM (2019-32)
Age-specific Cases of Sarcoidosis in the 7MM (2019-32)
Gender-specific Cases of Sarcoidosis in the 7MM (2019-32)

Sarcoidosis Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Sarcoidosis market or expected to be launched during the study period. The analysis covers Sarcoidosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Sarcoidosis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities:
https://www.delveinsight.com/report-store/sarcoidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Major Clinical, Commercial, and Regulatory Developments in the Sarcoidosis Therapeutics Market:
On January 18, 2023, aTyr Pharma, Inc. (Nasdaq: LIFE) announced that the European Commission (EC) granted orphan drug designation for the company's lead therapeutic candidate, efzofitimod, for the treatment of sarcoidosis based on the opinion of the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP).
On September 27, 2022, aTyr Pharma announced that it had dosed the first patient in the global pivotal EFZO-FIT™ study. The Phase 3 study will evaluate the efficacy and safety of the company's lead therapeutic candidate, efzofitimod, compared to placebo in patients with pulmonary sarcoidosis, a major form of interstitial lung disease (ILD).
On June 23, 2022, Xentria Inc. presented its first set of data showing its novel biologic, XTMAB-16, can potentially reduce the formation of sarcoidosis granulomas.
On December 15, 2020, Xentria announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for its intravenous TNF-α inhibitor, XTMAB-16, for the treatment of sarcoidosis. TNF-α is a proinflammatory cytokine that has been implicated in the pathogenesis of sarcoidosis and associated granuloma formation.

Sarcoidosis Therapeutics Assessment
Several major pharma and biotech companies are developing therapies for Sarcoidosis. Currently, Novartis is leading the therapeutics market with its Sarcoidosis drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Sarcoidosis Therapeutics Market Include:
AI Therapeutics
Amgen
Araim Pharmaceuticals
aTyr Pharma
Bayer
Bristol-Myers Squibb
Foresee Pharmaceuticals
Johnson and Johnson
Kinevant Sciences
Molecure
Morphosys
Nippon Shinyaku
Novartis
Pfizer
Relief Therapeutics
United Therapeutics
Xentria, Inc.
And Many Others

Sarcoidosis Drugs Covered in the Report Include:
BAY63-2521: Bayer
Cibinetide (ARA 290): Araim Pharmaceuticals
CMK389/ NOV-8: Novartis Pharmaceuticals/ Morphosys
Efzofitimod: aTyr Pharma
FP-020: Foresee Pharmaceuticals
Namilumab: Kinevant Sciences
OATD-01: Molecure
Rapamycin inhaled (LAM-001): AI Therapeutics
RLF-100 (aviptadil): Relief Therapeutics
Tyvaso (Inhaled Treprostinil): United Therapeutics
Uptravi (Selexipag): Johnson and Johnson/Nippon Shinyaku
XTMAB-16: Xentria, Inc.
And Many More

Learn More About the Emerging Therapies & Key Companies in the Sarcoidosis Therapeutics Market:
https://www.delveinsight.com/sample-request/sarcoidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Sarcoidosis Competitive Intelligence Analysis
4. Sarcoidosis Market Overview at a Glance
5. Sarcoidosis Background and Overview
6. Sarcoidosis Patient Journey
7. Sarcoidosis Epidemiology and Patient Population
8. Sarcoidosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Sarcoidosis Unmet Needs
10. Key Endpoints of Sarcoidosis Treatment
11. Sarcoidosis Marketed Products
12. Sarcoidosis Emerging Therapies
13. Sarcoidosis Seven Major Market Analysis
14. Attribute Analysis
15. Sarcoidosis Market Outlook (7 major markets)
16. Sarcoidosis Access and Reimbursement Overview
17. KOL Views on the Sarcoidosis Market.
18. Sarcoidosis Market Drivers
19. Sarcoidosis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings:
https://www.delveinsight.com/sample-request/sarcoidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Trending Market Research Reports 2032 | DelveInsight

Technical Due Diligence Firms- https://www.delveinsight.com/consulting/due-diligence-services

Vital Sign Monitors Devices Market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market

Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market

Anastomosis Device Market- https://www.delveinsight.com/report-store/anastomotic-leak-devices-market

Asperger Syndrome Market- https://www.delveinsight.com/report-store/asperger-syndrome-market

B-Cell Maturation Antigen Targeted Therapies Market- https://www.delveinsight.com/report-store/b-cell-maturation-antigen-targeted-therapies-market

UK Healthcare Report- https://www.delveinsight.com/report-store/uk-healthcare-outlook-report

Oncolytic Virus Cancer Therapy Pipeline- https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-pipeline-insight-2021

Shingles Market- https://www.delveinsight.com/report-store/shingles-market

Progressive Supranuclear Palsy Market- https://www.delveinsight.com/report-store/progressive-supranuclear-palsy-market

Tay-Sachs Disease Market- https://www.delveinsight.com/report-store/tay-sachs-disease-market

Shigellosis Market- https://www.delveinsight.com/report-store/shigellosis-market

Gene Therapy In CNS Disorder Market- https://www.delveinsight.com/report-store/gene-therapy-in-cns-disorder-market

Hypertrophic Cardiomyopathy Market- https://www.delveinsight.com/report-store/hypertrophic-cardiomyopathy-market

Varicella Zoster (HHV-3) Infections Market- https://www.delveinsight.com/report-store/varicella-zoster-hhv-3-infections-market

Vasculitis Market- https://www.delveinsight.com/report-store/vasculitis-market

Vascular Imaging Devices Market- https://www.delveinsight.com/report-store/vascular-imaging-market-market

Interbody Cages Market- https://www.delveinsight.com/report-store/interbody-cages-market

Acoustic Neuroma Market- https://www.delveinsight.com/report-store/acoustic-neuroma-market

Meningioma Market- https://www.delveinsight.com/report-store/meningioma-market

Age-related Vision Dysfunction Market- https://www.delveinsight.com/report-store/age-related-vision-dysfunction-market

Thymic Carcinoma Market- https://www.delveinsight.com/report-store/thymic-carcinoma-market

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.